Active substanceRimantadineRimantadine Similar drugsTo uncover Orvirem® syrup inwards d / children Remantadine® capsules inwards Olainfarm, AO Latvia Remantadine® pills inwards EN.S. PHARM, LTD. Russia Remantadine® pills inwards ROSFARM, LLC Russia Rimantadine pills inwards NGO Farmvilar, OOO Russia Rimantadine pills inwards ATOLL, LLC Russia Rimantadine pills inwards MARBIOFARM, OJSC Russia Rimantadine pills inwards TATHIMFARMPREPARATY, JSC Russia Rimantadine pills inwards MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia Rimantadine pills inwards BIOSINTEZ, PAO Russia Rimantadine pills inwards EVROFARM, CJSC Russia Rimantadine pills inwards MOSCOW ENDOCRINE FACTORY, FSUE Russia Rimantadine pills inwards UZOLE-SIBERIAN CHEMICAL PLANT, OJSC Russia Rimantadine pills inwards En.S. Pharmaceuticals, LLC Russia Rimantadine Avecsima pills inwards AVEKSIMA, JSC Russia Rimantadine Aktitab pills inwards OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia Rimantadine Kids syrup inwards d / children PHARMSTANDART-FORESTRY, OJSC Russia Dosage form: & nbspPills Composition:1 tablet contains:Active substance: rimantadine hydrochloride-50 mg;Excipients: lactose monohydrate (sugar milk) - 60 mg, potato starch - 37 mg, talc - 1.5 mg, stearic acid - 1.5 mg. Description:Tablets of white color of flat-cylindrical form with a facet. Pharmacotherapeutic group:An antiviral agent. ATX: & nbspJ.05.A.C Cyclic aminesJ.05.A.C.02 Rimantadine Pharmacodynamics:Rimantadine is active against various strains of the influenza A virus (especially A2 type). Being a weak ground, rimantadine acts by increasing the pH of the endosome, which have a membrane of vacuoles that surround the viral particles after they penetrate the cell. The prevention of acidification in these vacuoles blocks the fusion of the viral envelope with the endosome membrane, thus preventing the transfer of the viral genetic material to the cytoplasm of the cell.Rimantadine also inhibits the release of viral particles from the cell, i.e., interrupts the transcription of the viral genome. Pharmacokinetics:After oral administration rimantadine almost completely absorbed in the intestine. Absorption is slow. The connection with plasma proteins is about 40%. The volume of distribution: adults - 17-25 l / kg, children - 289 l / kg. Concentration in nasal secretion is 50% higher than plasma concentration. The maximum concentration of rimantadine in blood plasma (Cmax) with the intake of 100 mg once a day - 181 ng / ml, 100 mg twice a day - 416 ng / ml.Metabolised in the liver.The half-life (T1 / 2) is 24-36 h; display memory 15% - unaltered, 20% - in the form of hydroxy metabolites.In chronic renal failure, T1 / 2 increases by 2 times. In individuals with kidney failure and in elderly people, it can accumulate in toxic concentrations if the dose is not corrected in proportion to the decrease in creatinine clearance (CC). Indications:Early treatment and prevention of influenza A in adults and children older than 7 years. Contraindications:Increased sensitivity to the drug, acute liver disease, acute and chronic renal disease, hyperthyroidism, lactase deficiency, lactose intolerance, glucose-galactose malabsorption, pregnancy and lactation, infancy (up to 7 years). Carefully:Hypertension, epilepsy (including history), cerebral atherosclerosis, diseases of the gastrointestinal tract, hepatic failure, advanced age. Pregnancy and lactation:The use of the drug by pregnant women and women during breastfeeding is contraindicated. Dosing and Administration:Inside (after eating), washed down with water,according to the following scheme: adults are prescribed on the first day of the disease 100 mg 3 times; in the second and third days - 100 mg 2 times; the fourth day - 100 mg once. On the first day of the disease, the drug can be used once in a dose of 300 mg. Children from 7 to 10 years are prescribed 50 mg twice a day; 10-14 years 50 mg 3 times a day; over 14 years - doses for adults. The maximum daily dose for children should not exceed 150 mg.Treatment of influenza A should begin within 24-48 hours after the onset of symptoms of the disease and continue for 5-7 days. The optimal duration is not set.For the prevention of influenza in adults, 50 mg once a day for 10-15 days, depending on the focus of infection.For treatment of influenza in chronic renal failure (creatinine clearance less than 10 ml / min), severe hepatic insufficiency, epilepsy, elderly patients (including in nursing homes) - 100 mg once a day. Side effects:Rimantadine usually well tolerated. Sometimes there are: epigastric pain, diarrhea, indigestion, flatulence, dry mouth, anorexia (lack of appetite), nausea, vomiting; headache, dizziness, insomnia, neurological reactions, impaired concentration, drowsiness, anxiety, increased excitability, fatigue, ataxia,depression, euphoria, hyperkinesis, tremor, hallucinations, confusion, convulsions; pallor of the skin, palpitation, arterial hypertension, cerebrovascular disorder, heart block, tachycardia, fainting; ringing in the ears, a change in taste, a perversion of the sense of smell; shortness of breath, bronchospasm, cough; asthenia; Hyperbilirubinemia, allergic reactions (skin rash, itching, hives, etc.). Overdose:Data on overdose are absent. There may be an increase in side effects. Treatment: symptomatic, in the case of the recent administration of the drug - gastric lavage. Interaction:Pharmacodynamic: rimantadine reduces the effectiveness of antiepileptic drugs.Pharmacokinetic: adsorbents, astringents and enveloping agents reduce the absorption of rimantadine.Urine acidifying agents (ammonium chloride, ascorbic acid, etc.) reduce the effectiveness of rimantadine, due to a faster release of the latter kidneys.Urinary alkalizing agents (diacarb, sodium hydrogen carbonate and others) enhance the effectiveness of rimantadine due to a decrease in its secretion by the kidneys.Paracetamol and ascorbic acid reduce the maximum concentration of rimantadine in blood plasma by 11%.Cimetidine reduces the clearance of rimantadine by 18%. Special instructions:With the use of rimantadine, an exacerbation of chronic comorbidity may occur. In elderly patients with hypertension, the risk of hemorrhagic stroke increases. With a history of epilepsy and ongoing anticonvulsant therapy with rimantadine, the risk of epileptic seizures increases. In such cases rimantadine apply in a dose of 100 mg per day simultaneously with anticonvulsant therapy. Prophylactic reception is effective at contacts with the sick, with the spread of infection in closed collectives and at a high risk of the disease during the flu epidemic.Perhaps the emergence of drug-resistant viruses. Effect on the ability to drive transp. cf. and fur:During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions. Form release / dosage:Tablets 50 mg. Packaging:10 tablets per contour cell packaging made of polyvinylchloride film and aluminum foil.2 contour mesh packs together with instructions for use are placed in a pack of cardboard. Storage conditions:In a dry, dark place at a temperature of 2 to 25 ° C.Keep out of the reach of children. Shelf life:5 years. Do not use after the expiration date printed on the package. Terms of leave from pharmacies:On prescription Registration number:P N000175 / 01-2000 Date of registration:02.07.2010 The owner of the registration certificate:MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia Manufacturer: & nbspMOSHIMFARM PREPARATES them. NA Semashko OJSC Russia Information update date: & nbsp21.09.2015 Illustrated instructions × Illustrated instructions Instructions